Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Genetic Variation among Pharmacogenes in the Sardinian Population

Version 1 : Received: 26 July 2022 / Approved: 28 July 2022 / Online: 28 July 2022 (07:25:22 CEST)

A peer-reviewed article of this Preprint also exists.

Idda, M.L.; Zoledziewska, M.; Urru, S.A.M.; McInnes, G.; Bilotta, A.; Nuvoli, V.; Lodde, V.; Orrù, S.; Schlessinger, D.; Cucca, F.; Floris, M. Genetic Variation among Pharmacogenes in the Sardinian Population. Int. J. Mol. Sci. 2022, 23, 10058. Idda, M.L.; Zoledziewska, M.; Urru, S.A.M.; McInnes, G.; Bilotta, A.; Nuvoli, V.; Lodde, V.; Orrù, S.; Schlessinger, D.; Cucca, F.; Floris, M. Genetic Variation among Pharmacogenes in the Sardinian Population. Int. J. Mol. Sci. 2022, 23, 10058.

Abstract

Pharmacogenetics (PGx) aims to identify the genetic factors that determine inter-individual differences in response to drug treatment maximizing efficacy while decreasing the risk of adverse events. Estimating the prevalence of PGx variants involved in drug response, is a critical preparatory step for large-scale implementation of a personalized medicine program in a target population. Here, we profiled pharmacogenetic variation in fourteen clinically relevant genes in a representative sample set of 1,577 unrelated sequenced Sardinians -- an ancient island population that well accounts for genetic variation in Europe as a whole and, at the same time are enriched in genetic variants that are very rare elsewhere. To this end, we used PGxPOP, a PGx allele caller based on the guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), to identify the main phenotypes associated with the PGx alleles most represented in Sardinians. We estimate that 99.43% of Sardinian individuals may potentially respond atypically to at least one drug, that on average each individual is expected to have an abnormal response to about 17 drugs, and that for 27 drugs the fraction of the population at risk of atypical responses to therapy is more than 40%. Finally, we highlighted 174 pharmacogenetic variants for which the minor allele frequency is at least 10% higher among Sardinians as compared to other European populations, a fact that may contribute to substantial interpopulation variability in drug response phenotypes. This study provides baseline information for further large-scale pharmacogenomic investigations in the Sardinian population and underlines the importance of the PGx characterization of diverse than European populations as Sardinians.

Keywords

Pharmacogenetics; pharmacogenomics; precision medicine

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.